Global Action Fund for Fungal Infections
| Abbreviation | GAFFI |
|---|---|
| Purpose |
|
| Location |
|
| Fields | Fungal disease |
Board Chair | Oddi Aasheim |
| Website | Official website |
The Global Action For Fungal Infections (GAFFI), is an international foundation focussed on raising awareness of and collecting worldwide data on fungal disease. Its aim is to make reliable and inexpensive diagnostic tests widely available.
In 2015, GAFFI proposed action to make affordable fungal diagnostic tests and antifungal treatments available to 95% of the world's population by 2025. In 2018 GAFFI calculated that globally around one billion people have fungal infections of the skin, more than one million people become blind from fungal keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more than 300 million people have a severe fungal infection every year, of whom over 1.5 million die.
Location and members
[edit]The GAFFI is based in Switzerland and the United Kingdom. Its Board Chair is Oddi Aasheim Archived 2021-08-14 at the Wayback Machine.
Aims
[edit]GAFFI is an international foundation focussed on raising awareness of and collecting worldwide data on fungal disease burden Archived 2023-04-11 at the Wayback Machine. Its primary aims are to get reliable and inexpensive diagnostic tests to be widely available, particularly in low and middle income countries. The tests can be produced but the increasing cost of regulatory approval causes difficulty in getting them from the experimental stage in the laboratory to real world use in clinics.
Activities
[edit]GAFFI has successfully advocated for multiple diagnostics as Essential to be listed on the World Health Organization's EDL Archived 2023-04-11 at the Wayback Machine. GAFFI tracks country registration and access to Essential Medicines for antifungal agents Archived 2023-04-11 at the Wayback Machine. GAFFI also estimates and publicises data on fungal diseases incidence and prevalence (burden).
The GAFFI was launched in London in 2013 Archived 2023-04-11 at the Wayback Machine. In 2015, GAFFI proposed action to make fungal diagnostic tests and antifungal treatments available to 95% of the world's population by 2025 95/95 by 2025 Archived 2023-04-11 at the Wayback Machine. Six actions were proposed:
- Provide rapid diagnostic tests that do not rely on culture, and that are affordable.[1][2]
- Establish at least one laboratory in each country, led by fungal disease experts[1]
- Create clinical guidelines and teaching programmes[1]
- Better distribution of antifungal medicines on the WHO Model List of Essential Medicines[1]
- Establish fungal infection surveillance systems[1]
- Invest in public health mycology[1]
In 2018 the GAFFI calculated that globally around one billion people every year have fungal infections of the skin, more than one million people become blind from fungal keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more than 300 million people have severe fungal infections, of which over 1.5 million will die from it.[3]
In 2022, GAFFI published a report on access to diagnostics Archived 2023-04-11 at the Wayback Machine in 49 African countries, with the Africa Centre for Disease Control and Prevention. Many gaps remain.
References
[edit]- ^ a b c d e f Denning, David W. (1 July 2015). "The ambitious '95–95 by 2025' roadmap for the diagnosis and management of fungal diseases". Thorax. 70 (7): 613–614. doi:10.1136/thoraxjnl-2015-207305. ISSN 0040-6376. PMID 26024686. S2CID 2406405. Archived from the original on 14 August 2021. Retrieved 14 August 2021.
- ^ Gadd, Geoffrey M.; Sariaslani, Sima (June 2020). Advances in Applied Microbiology. Elsevier. p. 39. ISBN 978-0-12-820703-1.
- ^ Rodrigues, Marcio L.; Nosanchuk, Joshua D. (20 February 2020). "Fungal diseases as neglected pathogens: A wake-up call to public health officials". PLOS Neglected Tropical Diseases. 14 (2): e0007964. doi:10.1371/journal.pntd.0007964. ISSN 1935-2735. PMC 7032689. PMID 32078635.